Americans for Pharma Reform

Americans for Pharma Reform Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Americans for Pharma Reform, Nonprofit Organization, 7816 Rose Garden Lane, Springfield, VA.

🚨 OHIO - SEEKING YOUR FEEDBACK!Ohio families are paying 5 to 10 times MORE for the same prescription drugs - from the s...
05/31/2026

🚨 OHIO - SEEKING YOUR FEEDBACK!

Ohio families are paying 5 to 10 times MORE for the same prescription drugs - from the same companies - than people in other countries.

President Trump recently signed an Executive Order requiring drug companies to give Ohio - and all of America - the same low prices they charge everywhere else. It's called Most Favored Nation Prescription Pricing.

Do you SUPPORT or OPPOSE Most Favored Nation Pricing?

Share your position or any feedback you have about Big Pharma and Prescription Drugs below!

05/30/2026

The pharmaceutical industry's political math has always been built on one assumption: that voters won't connect what a senator took in contributions to how that senator voted on drug pricing. That math held for decades. A Senate primary just demonstrated it doesn't hold anymore. A senator who took millions from the pharmaceutical industry and blocked the president's own drug pricing policy finished third in his own party's primary in his own state. The industry's math is about money. The reform movement's math is about votes. Votes won a few Saturdays ago, and every member of Congress now calculating their position on MFN codification has a new data point to work with.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

05/29/2026

The pharmaceutical industry has spent millions framing Most Favored Nation pricing as socialism. Here's what it actually does: it says Americans — the customers paying the highest prices in the global pharmaceutical market — shouldn't pay more than the lowest price the same company already accepts from another developed nation for the exact same drug made in the exact same factory. In every other industry, charging your best and most loyal customers the highest price for an identical product isn't a market principle. It's a scandal. The word socialism is in this conversation because the industry put it there, and because it's cheaper than defending the actual pricing structure on its merits.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

05/29/2026

The pharmaceutical industry spends $452 million a year on lobbying — three lobbyists for every single member of Congress. That's the infrastructure standing between American patients and drug pricing relief, and it has kept reform stalled across multiple administrations regardless of public demand. One Senate primary just demonstrated it isn't invincible. The top Republican recipient of pharmaceutical industry money lost in his own state after blocking the president's own drug pricing policy. The machine spent $452 million last year and couldn't protect one senator from his own constituents.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

05/28/2026

The pharmaceutical industry spent 40 years moving production overseas while charging Americans premium prices throughout. The executives responsible for those offshoring decisions are now warning Congress that drug pricing reform threatens supply chain security. Drug pricing and supply chain security are two separate policy conversations that have been kept deliberately tangled because separating them is what causes both arguments to collapse — the supply chain argument loses its justification for protecting current prices, and the pricing argument that was sheltering behind it loses its cover.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

05/28/2026

The pharmaceutical industry has been warning Congress for two years that drug pricing reform would accelerate Chinese pharmaceutical dominance and threaten American innovation leadership. In 2024, those same companies spent $137 billion on research and development inside China. An industry investing $137 billion in Chinese pharmaceutical development while telling Congress that drug pricing reform is what threatens American security isn't making a national security argument. It's running the same blocking strategy it has always run — find the argument that puts reform on the wrong side of something Americans care about — through a new frame. In the 90s it was AIDS research. In the 2000s it was cancer. Today it's China.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

05/27/2026

The innovation argument for high drug prices requires a specific chain of events to hold. High prices generate revenue. That revenue funds research. That research produces breakthroughs that justify the price. In 2025, the pharmaceutical industry collected the revenue from high prices, cut $5.9 billion from research, and sent the difference to shareholders and executives. The chain requires all three steps. The 2025 financial filings document the first one and the reversal of the second, and those filings are audited public documents available to anyone who wants to check.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

05/27/2026

Bill Cassidy took more than a million dollars from the pharmaceutical industry, was the top Republican recipient of pharma money in the 2024 cycle, blocked MFN drug pricing from reaching a Senate vote, and finished third in his own party's primary in Louisiana on Saturday. The pharmaceutical industry is now warning Congress that Chinese pharmaceutical dominance is a reason not to pass MFN pricing. In 2024, that same industry spent $137.7 billion on R&D deals inside China. The voters of Louisiana just demonstrated they can tell the difference between a policy argument and a lobbying strategy. Congress should take note before the next primary cycle makes that point for them.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

05/24/2026

A pharmaceutical executive confirmed under Senate questioning that his company is profitable selling Ozempic in Paris, France for under $100. Americans pay $1,100 for the same injection. The senator's question was deliberately simple — not about R&D budgets or innovation investment, just whether the company makes money at the lower price. The answer was yes, on the record, under oath. The gap between $86 and $1,100 for the same drug from the same company is not explained by development costs. The executive just confirmed that.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

05/23/2026

A movie is a luxury. A streaming subscription is a luxury. Heart medication for a woman in her 70s on Social Security is not — and the pharmaceutical industry prices it with full knowledge of that difference. A senior choosing between filling her heart medication prescription and paying rent isn't a market failure. The industry has a specific term for the pricing methodology that produces that situation. They call it a profit matrix, and it's a description of deliberate design rather than an unintended outcome.

The podcast Big Pharma doesn't want you listening to — bustbigpharmapodcast.com/Platforms

Address

7816 Rose Garden Lane
Springfield, VA
22153

Website

Alerts

Be the first to know and let us send you an email when Americans for Pharma Reform posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Organization

Send a message to Americans for Pharma Reform:

Shortcuts

Share

Category